MedTrace Logo

Network-Level Mechanisms for Preclinical Alzheimer's Disease Development

NCT03461861 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2023-07-03

Study results available
· View outcomes & findings →

Summary

The purpose of this project is to test the hypothesis that AGB101 low dose levetiracetam extended release formulation can reduce abnormal hyperfunctional activity in the hippocampus in normal, healthy adults. The investigators will compare the functional connectivity results after taking AGB101 or placebo.

Conditions

  • APOE 4

Interventions

DRUG

AGB101 220 mg

AGB101 oral dose of 220 mg/day capsule, given as once-daily dosing.

OTHER

Placebo

Placebo, oral capsule given once-daily.

Sponsors & Collaborators

  • National Institute on Aging (NIA)

    collaborator NIH

  • Medical College of Wisconsin

    lead OTHER

Principal Investigators

  • Yang Wang, PhD · The Medical College of Wisconsin

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
55 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-04-11
Primary Completion
2021-03-31
Completion
2021-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03461861 on ClinicalTrials.gov